Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1091 of 6351
-
Cancer-Killing virus paired with immunotherapy shows promise in sarcoma trial
Disease control OngoingThe purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the abil…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a structured program help adults with autism build better relationships?
Symptom relief Recruiting nowThis project aims to examine the effectiveness of social skill training group in adults with autism spectrum disorders.
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Could a PARP inhibitor slow prostate cancer recurrence?
Disease control OngoingOlaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a radiographic response also had a PSA5 response. Ten of 11 re…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could chemo before surgery boost survival in pancreatic cancer?
Disease control CompletedIn patients with resectable pancreatic duct adenocarcinoma (PDAC), curative surgery followed by adjuvant chemotherapy is currently the standard of care. However, the long-term results are still poor, with median disease-free and overall survival of 14 months and 23 months. The co…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on bone marrow cancer
Disease control OngoingThe purpose of this phase I clinical trial is to test the safety of these CAR T cells in patients with myeloma. There are two parts of this study. Part 1 of the study consists of screening for BCMA, Lenalidomide assignment and cell collection. Part 2 of the study is treatment wi…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Drug combo shows promise against rare bone marrow cancer
Disease control OngoingThe purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a vaccine before standard therapy keep bladder cancer away?
Disease control OngoingThis randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscl…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can talk therapy and social coaching ease early psychosis?
Disease control CompletedCognitive-behavioral therapy (CBT) and social skills training (SST) are recommended psychological interventions to improve symptomatology and functional recovery in psychosis. In addition, CBT may reduce hyperactivation of the brain structures responsible for the stress response.…
Sponsor: Hospital Clinic of Barcelona • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination wi…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Immunotherapy offers hope for young women with rare, Chemo-Resistant cancer
Disease control CompletedGestational trophoblastic neoplasias (GTN) are characterized by the persistence of elevated hCG titers after complete uterine evacuation of a partial hydatidiform mole (PHM) or a complete hydatidiform mole. GTN patients are commonly treated with single agent treatment (methotrexa…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Heart scans could spare patients from invasive catheter procedures
Diagnosis CompletedPulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and eventually to death. The therapeutic strategy has become complex and needs to perform recurring follow up evaluations includi…
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New drug shows promise for rare joint tumor in early trial
Disease control OngoingThis is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant s…
Phase 1/2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lab-grown immune cells take on seven viruses in transplant patients
Disease control OngoingThis Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors. In…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as n…
Phase 1/2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a simple silicone ring prevent preterm birth?
Disease control Stopped earlyThe purpose of the study is to determine whether the Arabin pessary is a useful intervention of preterm birth at less than 37 weeks in women with a singleton gestation and a short cervix.
Phase 3 • Sponsor: The George Washington University Biostatistics Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Brain cancer hope: new drugs tested in major trial
Disease control Recruiting nowThis research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC…
Phase 2 • Sponsor: David Reardon, MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug duo aims to stop smoldering myeloma from becoming full-blown cancer
Disease control OngoingThis is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gas therapy may shield kidneys during heart surgery
Disease control CompletedThe purpose of this study is to determine whether nitric oxide is effective in the treatment of acute kidney injury in cardiac surgical patients with sign and laboratory data suggesting endothelial dysfunction undergoing prolonged cardiopulmonary bypass.
Phase 3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy shows promise against rare skin cancer
Disease control OngoingThis pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can be removed by surgery (resectable) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may hel…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC